Development of nanocarriers for the intracellular delivery of proteins drugs

Chemotherapy is still the principal treatment option for metastatic tumors. However, due to its side effects, alternative therapies are being studied. In this regard, the use of nano-encapsulated proteins increase the specificity and the efficacy of the therapy. In fact, proteins are highly specific...

Descripción completa

Detalles Bibliográficos
Autor: Gonella, Andrea
Tipo de recurso: tesis doctoral
Fecha de publicación:2019
País:España
Institución:Universidad de Santiago de Compostela (USC)
Repositorio:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Idioma:inglés
OAI Identifier:oai:minerva.usc.gal:10347/20145
Acceso en línea:http://hdl.handle.net/10347/20145
Access Level:acceso abierto
Palabra clave:Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentos
Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320990 Farmacología experimental
id ES_0f8ef3f8fc947373d3b8f5d88d2dfd56
oai_identifier_str oai:minerva.usc.gal:10347/20145
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of nanocarriers for the intracellular delivery of proteins drugsGonella, AndreaMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentosMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320990 Farmacología experimentalChemotherapy is still the principal treatment option for metastatic tumors. However, due to its side effects, alternative therapies are being studied. In this regard, the use of nano-encapsulated proteins increase the specificity and the efficacy of the therapy. In fact, proteins are highly specific and selective, while the nanocarriers could favor several advantages in term of tumor targeting and penetration, drug protection and enhanced half-life. Hence, the formation of hyaluronic acid based nanocarriers encapsulating proteins is presented in this manuscript. The nanocarriers have been initially used for encapsulating model proteins (BSA and IgG). Several formulation technologies have been tested and the obtained knowledge have been finally used for associating the monoclonal antibody bevacizumab. It has been demonstrated that this last formulation is internalized by a breast cancer cell line while no significant effects have been obtained in vivo (breast cancer mice model) compare to the negative controls.Alonso Fernández, María JoséTorres López, DoloresUniversidade de Santiago de Compostela. Centro Internacional de Estudos de Doutoramento e Avanzados (CIEDUS)Universidade de Santiago de Compostela. Escola de Doutoramento Internacional en Ciencias da Saúde20192019-01-0120192019-01-01doctoral thesishttp://purl.org/coar/resource_type/c_db06info:eu-repo/semantics/doctoralThesisapplication/pdfhttp://hdl.handle.net/10347/20145reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostelainstname:Universidad de Santiago de Compostela (USC)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution-NonCommercial-NoDerivatives 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:minerva.usc.gal:10347/201452026-06-15T12:47:27Z
dc.title.none.fl_str_mv Development of nanocarriers for the intracellular delivery of proteins drugs
title Development of nanocarriers for the intracellular delivery of proteins drugs
spellingShingle Development of nanocarriers for the intracellular delivery of proteins drugs
Gonella, Andrea
Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentos
Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320990 Farmacología experimental
title_short Development of nanocarriers for the intracellular delivery of proteins drugs
title_full Development of nanocarriers for the intracellular delivery of proteins drugs
title_fullStr Development of nanocarriers for the intracellular delivery of proteins drugs
title_full_unstemmed Development of nanocarriers for the intracellular delivery of proteins drugs
title_sort Development of nanocarriers for the intracellular delivery of proteins drugs
dc.creator.none.fl_str_mv Gonella, Andrea
author Gonella, Andrea
author_facet Gonella, Andrea
author_role author
dc.contributor.none.fl_str_mv Alonso Fernández, María José
Torres López, Dolores
Universidade de Santiago de Compostela. Centro Internacional de Estudos de Doutoramento e Avanzados (CIEDUS)
Universidade de Santiago de Compostela. Escola de Doutoramento Internacional en Ciencias da Saúde
dc.subject.none.fl_str_mv Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentos
Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320990 Farmacología experimental
topic Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentos
Materias::Investigación::32 Ciencias médicas::3209 Farmacología::320990 Farmacología experimental
description Chemotherapy is still the principal treatment option for metastatic tumors. However, due to its side effects, alternative therapies are being studied. In this regard, the use of nano-encapsulated proteins increase the specificity and the efficacy of the therapy. In fact, proteins are highly specific and selective, while the nanocarriers could favor several advantages in term of tumor targeting and penetration, drug protection and enhanced half-life. Hence, the formation of hyaluronic acid based nanocarriers encapsulating proteins is presented in this manuscript. The nanocarriers have been initially used for encapsulating model proteins (BSA and IgG). Several formulation technologies have been tested and the obtained knowledge have been finally used for associating the monoclonal antibody bevacizumab. It has been demonstrated that this last formulation is internalized by a breast cancer cell line while no significant effects have been obtained in vivo (breast cancer mice model) compare to the negative controls.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-01-01
2019
2019-01-01
dc.type.none.fl_str_mv doctoral thesis
http://purl.org/coar/resource_type/c_db06
dc.type.openaire.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
dc.identifier.none.fl_str_mv http://hdl.handle.net/10347/20145
url http://hdl.handle.net/10347/20145
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution-NonCommercial-NoDerivatives 4.0 Internacional
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
instname:Universidad de Santiago de Compostela (USC)
instname_str Universidad de Santiago de Compostela (USC)
reponame_str Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
collection Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403460815814656
score 15,81155

Similares en LA Referencia